Hypertension Clinical Trial
Official title:
A Cohort Study of Telmisartan on Metabolic Components and Left Ventricular Remodeling in Obese Patients With Hypertension
Hypertension is closely related to metabolic abnormalities such as obesity, dyslipidemia and diabetes. When hypertension is complicated with metabolic abnormalities, target organ damage is more serious, the risk of cardiovascular adverse events is greater, and the treatment is more complex. The pathophysiological mechanism of obesity-associated hypertension has its particularity. Blood pressure control and effective control of obesity are important therapeutic targets. At present, there are no guidelines for the treatment of obesity-associated hypertension. Although several drugs have certain effects on fat metabolism, they have little effect on blood pressure and have some side effects in long-term use. Among the existing antihypertensive drugs, angiotensin II type 1 receptor (AT-1) antagonists have shown their particularity in improving glycolipid metabolism, but strict clinical trials are needed to confirm their effectiveness in weight loss and metabolism improvement. Previous studies have shown that obese patients with hypertension have severe insulin resistance, poor glycolipid metabolism and are prone to cardiovascular damage. Telmisartan can block AT-1 receptor and partially activate PPAR-γ, increase the expression of PPAR-γ target gene in preadipocytes, improve the function of visceral adipose tissue, and effectively prevent obesity-related cardiovascular diseases. It is presumed that telmisartan can act as a PPAR-γ agonist in clinic by altering the metabolic components and insulin sensitivity, but there is no clinical evidence for this. On the basis of previous studies, this study aims to evaluate the clinical efficacy of telmisartan or amlodipine in controlling blood pressure, reducing fat accumulation, improving insulin sensitivity, and reducing cardiac remodeling in obese patients with hypertension by prospective cohort study.
At present, there are no guidelines for the treatment of obese patients with hypertension.
Blood pressure control and effective control of obesity are important therapeutic targets for
obesity-associated hypertension. Whether telmisartan can be used as PPAR-γ agonist, unlike
other AT-1 receptor antagonists and calcium channel blockers amlodipine, can improve the
visceral adipose tissue function and cardiac remodeling in obese patients with hypertension
by altering their metabolic components and insulin sensitivity while controlling blood
pressure. There is no evidence that telmisartan can reduce cardiac remodeling in obese
patients with hypertension.
1.Research contents:
1. To evaluate the clinical efficacy of telmisartan or amlodipine in controlling blood
pressure, reducing fat accumulation, improving glycolipid metabolism and insulin
sensitivity, and reducing cardiac remodeling in obese patients with hypertension;
2. To evaluate whether telmisartan can alter metabolic components and insulin sensitivity,
improve visceral adipose tissue function and reduce cardiac remodeling in obese patients
with hypertension by blocking AT-1 receptor and partially activating PPAR-gamma, which
is different from other AT-1 receptor antagonists and calcium channel blockers
amlodipine.
2.Research population 2.1 Entry criteria
Only those who possess the following four conditions can enter the study:
1. Essential hypertension patients (including confirmed hypertension without regular
treatment, average blood pressure (≥160 or/and 100 mmHg) in two follow-up visits; or
hypertension under combined antihypertensive treatment; or unsatisfactory blood pressure
control with single drug treatment, blood pressure above 140 or/and 90 mmHg);
2. Age ranges from 18 to 79;
3. Body mass index, BMI (≥30 kg/m2), or waist circumference, male (≥102 cm), female (≥ 88
cm);
4. Ability to provide informed consent。
2.2 exclusion criteria
One of the following is not included:
(1) secondary hypertension; (2) acute cardiovascular and cerebrovascular events within 3
months; (3) severe cardiomyopathy, rheumatic heart disease, congenital heart disease;(4)
unstable angina pectoris; (5) severe liver or kidney disease (ALT increased by 2 times;
Creatinine > 2. 5 mg/dL); (6) malignant tumors; (7) gout; (8) women who are taking birth
control pills or are at risk of pregnancy; (9) have a history of allergy to research drugs;
(10) patients with specific contraindications to the study drugs; (11) participants in other
clinical trials; (12) patients with difficulty in long-term follow-up or poor compliance;
(13) the competent doctor considers it inappropriate to participate in clinical research.
3.The input information of the subjects
1. Sample source: Since December 2018, patients with essential hypertension were diagnosed
in the First Affiliated Hospital of Xi'an Jiaotong University and treated with
telmisartan or amlodipine alone under the guidance of doctors;
2. Recruitment procedures: selecting the subjects according to inclusion and exclusion
criteria, and signing informed consent.
4.Criteria for termination or withdrawal of research subjects
1. Those who need revascularization because of myocardial infarction and unstable angina
pectoris;
2. Heart failure;
3. Stroke.
5. Study Groups
1. Telmisartan group: Telmisartan 80 mg once a day
2. amlodipine group: amlodipine 5 mg once a day
6.Research evaluation index
1. Baseline indicators: age, sex, occupation, height, weight, BMI, waist-hip circumference,
systolic blood pressure, diastolic blood pressure, heart rate;
2. Metabolic indicators: blood lipid, liver function, kidney function, oral glucose
tolerance test, simultaneous insulin release test, plasma Glucagon, plasma aldosterone,
plasma angiotensin II, abdominal fat distribution
3. Fat function: serum leptin, serum adiponectin, serum TNFalpha, serum IL-6, serum hs-CRP,
serum PPAR-γ;
4. Cardiac remodeling: echocardiographic parameters .
7.Research steps
1. Clinical trials are ethically reviewed by ethics committees, and clinical trials are
registered;
2. Collect cases according to inclusion and exclusion criteria, collect medical history
data of subjects, and complete follow-up. At the same time, clinical and biochemical
experiments were carried out;
3. Comprehensive analysis of experimental data, repetition and supplementation of necessary
molecular biological experiments, comprehensive summary of the results, writing and
publishing SCI papers and Chinese core journal papers.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |